Feasibility study of ABCP therapy and an exploratory study of microbiota in Japanese patients with advanced non-squamous non-small-cell lung cancer

Feasibility study of ABCP (Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel) therapy and an exploratory study of microbiota in Japanese patients with advanced non-squamous non-small-cell lung cancer - Keihin area's next generation research for checkpoint inhibitor and immuno-oncology (Kangaroo-Tail: K-TAIL) 201

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031200088

Enrollment

Registered

2020-08-19

Start date

2020-10-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squamous Non-small cell lung cancer Non-squamous Non-small cell lung cancer

Interventions

Induction treatment Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel was administered for four or six 21-day cycles. Maintenance treatment Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel was administer

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: We determine patients who are obtained document agreement by free will after the explanation using informed consent form, satisfy all of the following selection criteria, do not conflict with exclusion criteria, have been judged to be eligible for participation in this study by the research doctor as subjects. 1)Histologically confirmed non-squamous non-small cell lung cancer 2)Patients with unknown driver mutation, or without a driver mutation in the EGFR, ALK, ROS1, or BRAF are eligible. Patients with a driver mutation in the EGFR, ALK, ROS1, or BRAF must have experienced disease progression (during or after treatment) or intolerance to treatment with one or more kinase inhibitors. 3)Measurable lesion by RECIST ver1.1 4)Age: Age at agreement acquisition is over 20years old 5)Performance status 0 to 1 (ECOG) 6)Life expectancy is at least 3 months 7)Adequate organ function

Exclusion criteria

Exclusion criteria: We exclude persons who corresponding to any of the following criteria from this study. 1)Medical history that may have an impact on the evaluation and safety of this study (heart, liver, kidney, lung, blood disorder etc.) 2)History or complication of autoimmune disease 3)Continuously using systemic corticosteroid 4)Pericardial, pleural effusion or ascites to need drainage 5)Pregnant or lactating women, or men and women with wanting pregnancy 6)Persons who has been judged unsuitable as subjects of this study by the research doctor

Design outcomes

Primary

Measure	Time frame
Rate of progression-free survival at 6 months	—

Secondary

Measure	Time frame
Rate of objective response Progression-free survival Overall survival Adverse events Relationship between rate of progression-free survival at 6 months, rate of objective response , progression-free survival and Microbiota.	—

Contacts

Public ContactAtsushi Horiike

Showa University Hospital

horiike@med.showa-u.ac.jp+81-3-3784-8402

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026